Corona Remedies IPO
Corona Remedies IPO — date, price band, GMP & allotment 2025
Corona Remedies IPO is attracting investor attention as the company operates in branded generic pharmaceuticals across key therapeutic segments in India. The company has a strong presence in women’s healthcare, cardiology, and dermatology. With consistent revenue growth and an expanding product portfolio, the IPO is expected to support future expansion and debt reduction. Investors are watching subscription levels and valuation before making investment decisions.
Stock price
Corona Remedies is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 15 September.
- Open 08 Dec 2025
- Close 10 Dec 2025
- Allotment 11 Dec 2025
- Refund/credit 12 Dec 2025
- Listing 15 Dec 2025
Issue summary
The terms of the offer, as filed.
| IPO Dates | 8 to 10 Dec, 2025 |
|---|---|
| Price Band | ₹1,008 – 1,062 |
| Face Value | ₹₹10 |
| Lot Size | 14 Shares |
| Issue Size | ₹655.37 Cr |
| Sale Type | OFS only |
| Listing On | BSE, NSE |
| Employee Discount | ₹54 |
| Registrar | KFin Technologies Limited |
| Min Investment | ₹ 14,868 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 14 shares at the ₹1062 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 14 | ₹14,868 |
| Retail (max) | 13 | 182 | ₹1,93,284 |
| S-HNI (min) | 14 | 196 | ₹2,08,152 |
| S-HNI (max) | 67 | 938 | ₹9,96,156 |
| B-HNI (min) | 68 | 952 | ₹10,11,024 |
Three years of numbers
All figures in ₹ crore, as reported in the Corona Remedies offer document.
| Metric | 30 jun 25 | 31 mar 25 | 31 Mar 24 |
|---|---|---|---|
| Revenue | 348.56 | 1,202.35 | 1,020.93 |
| OPM % | 24.29 | 23.32 | |
| EBITDA | 71.80 | 245.91 | 161.19 |
| Net Profit | 46.20 | 149.43 | 90.50 |
| Debt | 106.65 | 62.70 | 134.14 |
| Assets | 1,012.38 | 929.86 | 830.58 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Corona Remedies RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Corona Remedies IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Post-Issue |
|---|---|
| EPS (₹) | ₹24.43 |
| P/E Ratio (x) | 58.26 |
| Market Cap at Offer Price (₹ Cr) | ₹2,008.37 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹1062 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹51.96 Cr of the issue is earmarked to named objects.
About the company
The company’s product portfolio consists primarily of branded generic medicines, including tablets, capsules, syrups and injectables, catering to both acute and chronic therapies. Corona Remedies follows an asset-light business model, where manufacturing is largely outsourced to WHO-GMP certified third-party facilities while it focuses on marketing, branding and distribution. This allows the company to maintain flexibility and control costs while ensuring consistent product quality. Its strategy revolves around launching differentiated products, building strong doctor relationships and expanding into new therapeutic areas. With a steady focus on research-backed marketing and efficient supply chain management, Corona Remedies aims to sustain long-term growth and strengthen its position in the Indian pharmaceutical industry.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
+91 20 46702222.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Corona Remedies IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
JM Financial Ltd.
29 issues handledBest listing: Tempsens Instruments (India) (+111.3%). Weakest: Turtlemint Fintech Solutions (-10.4%).
Kotak Mahindra Capital Co.Ltd.
15 issues handledBest listing: Dhoot Transmission (+37.8%). Weakest: Amagi Media Labs (-12.2%).
IIFL Capital Services Limited
25 issues handledBest listing: Kusumgar (+37.0%). Weakest: Purple Style Labs (-7.0%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Corona Remedies?
The current Grey Market Premium is ₹300, or 484% over the issue price.
What is the Corona Remedies IPO price band?
₹1 to ₹008, on a face value of ₹₹10.
When is the allotment?
The basis of allotment is 11 December 2025, with listing on 15 December 2025.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — KFin Technologies Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
